This trial is an open label two-arm randomised trial focused on identifying the best treatment for community acquired sepsis patients. We will be investigating the feasibility of delivering early intravenous fluid resuscitation by comparing 5% human albumin solution (HAS) to balanced crystalloid. Currently, balanced crystalloids are used as routine care and the first line therapy in the international sepsis guidelines, whereas HAS is the second line fluid therapy in septic shock. Although, studies are showing that HAS may have further potential benefits to patients with sepsis.
The study aims to recruit 300 patients who meet the following inclusion criteria:
Patients will be recruited in the Emergency Department and Medical and Surgical Assessment Units across UK NHS hospitals. The treatment will be administered within the first 6 hours of randomisation. Following this, patients will be reviewed for safety reasons and asked to complete a questionnaire in order to evaluate thier quality of life.
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions